Effects of B7-blocking agent and/or CsA on induction of platelet-specific T-cell anergy in chronic autoimmune thrombocytopenic purpura

Blood

Volumn 101, Issue 7, 2003, Pages 2721-2726

  Peng, Jun ^a   Liu, Chuanfang ^b   Liu, Dai ^b   Ren, Cuiai ^b   Li, Wei ^b   Wang, Zhenguang ^b   Xing, Nianzeng ^b   Xu, Conggao ^b   Chen, Xueliang ^b   Ji, Chunyan ^b   Zhang, Maohong ^b   Hou, Ming ^b  

^a SHANDONG UNIVERSITY   (China)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN A; CYTOLOGIC T LYMPHOCYTE ASSOCIATED ANTIGEN 4 IMMUNOGLOBULIN; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 2; THROMBOCYTE ANTIGEN; UNCLASSIFIED DRUG; ABATACEPT; ANTIBODY CONJUGATE; B7 ANTIGEN; CYCLOSPORIN;

ADOLESCENT; ADULT; ARTICLE; AUTOIMMUNE DISEASE; CELL CULTURE; CELL ISOLATION; CLINICAL ARTICLE; CLONAL ANERGY; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HUMAN; HUMAN CELL; IMMUNOLOGICAL TOLERANCE; MALE; PRIORITY JOURNAL; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; THROMBOCYTE; THROMBOCYTOPENIC PURPURA; CASE CONTROL STUDY; CHILD; CHRONIC DISEASE; CYTOLOGY; DRUG COMBINATION; DRUG EFFECT; IDIOPATHIC THROMBOCYTOPENIC PURPURA; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; MIDDLE AGED; PROSPECTIVE STUDY; TREATMENT OUTCOME;

ADOLESCENT; ADULT; ANTIGENS, CD80; ANTIGENS, HUMAN PLATELET; BLOOD PLATELETS; CASE-CONTROL STUDIES; CHILD; CHRONIC DISEASE; CLONAL ANERGY; CYCLOSPORINE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; IMMUNE TOLERANCE; IMMUNOCONJUGATES; LYMPHOCYTE ACTIVATION; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC; T-LYMPHOCYTES; TREATMENT OUTCOME;

EID: 0038784372     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2002-06-1666     Document Type: Article

References (38)

1. Imbach P, Kuhne T. Immune thrombocytopenic purpura ITP. Vox Sang. 1998;74(suppl 2):309-314.
2. Kuwana M, Kaburaki J, Ikeda Y. Autoreactive T cells to platelet GPIIb-IIIa in immune thrombocytopenic purpura: role in production of anti-platelet autoantibody. J Clin Invest. 1998;102:1393-1402.
3. Hedlund-Treutiger I, Wahlstrom J, Elinder G. Role of the T cell receptor in idiopathic thrombocytopenic purpura (ITP). Acta Paediatr Suppl. 1998;424:46-50.
4. Semple JW, Lazarus AH, Freedman J. The cellular immunology associated with autoimmune thrombocytopenic purpura: an update. Transfus Sci. 1998;19:245-251.
5. Semple JW, Freedman J. Increased antiplatelet T helper lymphocyte reactivity in patients with autoimmune thrombocytopenia. Blood. 1991;78:2619-2625.
6. Semple JW, Milev Y, Cosgrave D, et al. Differences in serum cytokine levels in acute and chronic autoimmune thrombocytopenic purpura: relationship to platelet phenotype and antiplatelet T-cell reactivity. Blood. 1996;87:4245-4254.
7. Ware RE, Howard TA. Phenotypic and clonal analysis of T lymphocytes in childhood immune thrombocytopenic purpura. Blood. 1993;82:2137-2142.
8. Shimomura T, Fujimura K, Takafuta T, et al. Oligoclonal accumulation of T cells in peripheral blood from patients with idiopathic thrombocytopenic purpura. Br J Haematol. 1996;95:732-737.
9. Zhang Y, Lorre K, de Boer M, Ceuppens JL. B7-blocking agents, alone or in combination with cyclosporin A, induce antigen-specific anergy of human memory T cells. J Immunol. 1997;158:4734-4740.
10. Geginat J, Clissi B, Moro M, Dellabona P, Bender JR, Pardi R. CD28 and LFA-1 contribute to cyclosporin A-resistant T cell growth by stabilizing the IL-2 mRNA through distinct signaling pathways. Eur J Immunol. 2000;30:1136-1144.
11. Ghosh P, Sica A, Cippitelli M, et al. Activation of nuclear factor of activated T cells in a cyclosporin A-resistant pathway. J Biol Chem. 1996;271:7700-7704.
12. Schweitzer AN, Sharpe AH. Studies using antigen-presenting cells lacking expression of both B7-1 (CD80) and B7-2 (CD86) show distinct requirements for B7 molecules during priming versus restimulation of Th2 but not Th1 cytokine production. J Immunol. 1998;161:2762-2771.
13. Chang TT, Jabs C, Sobel RA, Kuchroo VK, Sharpe AH. Studies in B7-deficient mice reveal a critical role for B7 costimulation in both induction and effector phases of experimental autoimmune encephalomyelitis. J Exp Med. 1999;190:733-740.
14. Peterson KE, Sharp GC, Tang H, Braley-Mullen H. B7.2 has opposing roles during the activation versus effector stages of experimental autoimmune thyroiditis. J Immunol. 1999;162:1859-1867.
15. Finck BK, Linsley PS, Wofsy D. Treatment of murine lupus with CTLA4-Ig. Science. 1994;265:1225-1227.
16. Abrams JR, Kelley SL, Hayes E, et al. Blockade of T lymphocyte costimulation with cytotoxic T lymphocyte-associated antigen 4-immunoglobulin (CTLA4Ig) reverses the cellular pathology of psoriatic plaques, including the activation of keratinocytes, dendritic cells, and endothelial cells. J Exp Med. 2000;192:681-694.
17. Kamradt T, Mitchison NA. Tolerance and autoimmunity. N Engl J Med. 2001;344:655-664.
18. Shi FD, He B, Li H, Matusevicius D, Link H, Ljunggren HG. Differential requirements for CD28 and CD40 ligand in the induction of experimental autoimmune myasthenia gravis. Eur J Immunol. 1998;28:3587-3593.
19. Allison J, Stephens LA, Kay TW, et al. The threshold for autoimmune T cell killing is influenced by B7-1. Eur J Immunol. 1998;28:949-960.
20. Lenschow DJ, Ho SC, Sattar H, et al. Differential effects of anti-B7-1 and anti-B7-2 monoclonal antibody treatment on the development of diabetes in the nonobese diabetic mouse. J Exp Med. 1995;181:1145-1155.
21. Tada Y, Nagasawa K, Ho A, et al. CD28-deficient mice are highly resistant to collagen-induced arthritis. J Immunol. 1999;162:203-208.
22. Van Gool SW, de Boer M, Ceuppens JL. The combination of anti-B7 monoclonal antibody and cyclosporin A induces alloantigen-specific anergy during a primary mixed lymphocyte reaction. J Exp Med. 1994;179:715-720.
23. Emilia G, Messora C, Longo G, Bertesi M. Long-term salvage treatment by cyclosporin in refractory autoimmune haematological disorders. Br J Haematol. 1996;93:341-344.
24. Schultz KR, Strahlendorf C, Warrier I, Ravindranath Y. Cyclosporin A therapy of immunemediated thrombocytopenia in children [letter]. Blood. 1995;85:1406-1408.
25. Kappers-Klunne MC, van't Veer MB. Cyclosporin A for the treatment of patients with chronic idiopathic thrombocytopenic purpura refractory to corticosteroids of splenectomy. Br J Haematol. 2001;114:121-125.
26. George JN, Woolf SH, Raskob GE, et al. Idiopathic thrombocytopenic purpura: a practice guideline developed by explicit methods for the American Society of Hematology. Blood. 1996;88:3-40.
27. Garcia-Suarez J, Prieto A, Reyes E, Manzano L, Merino JL, Alvarez-Mon M. The clinical outcome of autoimmune thrombocytopenic purpura patients is related to their T cell immunodeficiency. Br J Haematol. 1993;84:464-470.
28. Garcia-Suarez J, Prieto A, Manzano L, Reyes E, Molto L, Alvarez-Mon M. T lymphocytes from autoimmune thrombocytopenic purpura show a defective activation and proliferation after cytoplasmic membrane and intracytoplasmic mitogenic signals. Am J Hematol. 1993;44:1-8.
29. Rapoport MJ, Lazarus AH, Jaramillo A, Speck E, Delovitch TL. Thymic T cell anergy in autoimmune nonobese diabetic mice is mediated by deficient T cell receptor regulation of the pathway of p21 ras activation. J Exp Med. 1993,177:1221-1226.
30. Bachmaier K, Pummerer C, Shahinian A, et al. Induction of autoimmunity in the absence of CD28 costimulation. J Immunol. 1996;157:1752-1757.
31. Greenfield EA, Ngugen KA, Kuchroo VK. CD28/B7 costimulation: a review. Crit Rev Immunol. 1998;18:389-418.
32. Wingren AG, Parra E, Varga M, et al. T cell activation pathways: B7, LFA-3, and ICAM-1 shape unique T cell profiles. Crit Rev Immunol. 1995;15:235-253.
33. + immunoregulatory T cells that control autoimmune diabetes. Immunology. 2000;12:431-440.
34. Kolesnick R, Golde DW. The sphingomyelin pathway in tumor necrosis factor and interleukin-1 signaling. Cell. 1994;77:325-328.
35. Kalli K, Huntoon C, Bell M, McKean DJ. Mechanism responsible for T-cell antigen receptor- and CD28- or interleukin 1 (IL-1) receptor-initiated regulation of IL-2 gene expression by NF-kappaB. Mol Cell Biol. 1998;18:3140-3148.
36. Filion MC, Bradley AJ, Devine DV, Decary F, Chartrand P. Autoreactive T cells in healthy individuals show tolerance in vitro with characteristics similar to but distinct from clonal anergy. Eur J Immunol. 1995;25:3123-3127.
37. Filion MC, Proulx C, Bradley AJ, et al. Presence in peripheral blood of healthy individuals of autoreactive T cells to a membrane antigen present on bone marrow-derived cells. Blood. 1996,88:2144-2150.
38. van Parijs L, Perez VL, Abbas AK. Mechanisms of peripheral T cell tolerance. Novartis Found Symp. 1998;215:5-20, 33-40.